Oncimmune Holdings PLC Grant of Options and PDMR Dealing (2274W)
09 December 2023 - 1:32AM
UK Regulatory
TIDMONC
RNS Number : 2274W
Oncimmune Holdings PLC
08 December 2023
8 DECEMBER 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
today announces that as part of its management incentivisation
scheme, options ("Options") to subscribe for 105,263 ordinary
shares of GBP0.01 each in the Company ("Ordinary Shares") were
granted on 8 December 2023 to Martin Hudson, Finance Director.
Following this grant, Mr Hudson holds Options over a total of
105,263 Ordinary Shares, representing approximately 0.14 per cent
of the Company's issued share capital of 74,142,147. Other than the
grant of the Options, neither Mr Hudson nor any of his connected
persons have any beneficial interest in Ordinary Shares.
The Options have been granted under the Oncimmune Holdings Plc
2016 Unapproved and EMI Share Option Plan, have an exercise price
of GBP0.266, being the closing price of Ordinary Shares on 7
December 2023, and vest annually in five equal parts from the date
of grant until the fifth anniversary of the grant.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
Notification and public disclosure of transactions by person
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Mr Martin Hudson
--------------------------------------- --------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------------
a) Position/status Finance Director
--------------------------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
--------------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
--------------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BYQ94H38
b) Nature of the transaction Grant of options
--------------------------------------- --------------------------------------
c) Price(s) and volume(s)
----------------- ----------------
Price(s) Volume(s)
----------------- ----------------
GBP0.266 105,263
-------------------------------------------------------------- ----------------
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 8 December 2023
--------------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------------- --------------------------------------
For further information:
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a global leader in immune biomarkers and
immunodiagnostics, offering autoantibody biomarker profiling in
immunooncology, autoimmune and infectious diseases. Through its
ImmunoINSIGHTS(TM) technology platform, the Company provides
insights and analytics to discover and validate novel biomarkers,
improve treatment responses and adverse event (irAE) prediction,
patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK, with its discovery and
development facility based in Dortmund, Germany and a business
development team based in the US and Europe.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFSFFLAEDSEDE
(END) Dow Jones Newswires
December 08, 2023 09:32 ET (14:32 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024
